On July 10th, Global Health released an announcement that cosmetics with KX-826 as the main ingredient, which was independently developed by the company and officially named by the International Nomenclature of Cosmetic Ingredients ("INCI"), has recently been launched globally, with the first product being an external hair loss prevention lotion ("new product") targeting androgenetic alopecia ("AGA"). The group will further explore the effectiveness of using KX-826 in the fields of AGA and acne, actively enrich product lines, increase promotion to target users, and meet the needs of different usage scenarios. The company believes that the launch and sale of new products will bring stable income and cash flow to the group, and bring long-term benefits to the group as a whole.
KX-826 is one of the core innovative products of the group. During its development, multiple clinical trials for the treatment of AGA in both men and women have been completed in China and the United States, demonstrating excellent safety and significant effectiveness in preventing hair loss and promoting hair growth. The launch and sale of new products is the first commercial attempt of KX-826 in the dermatology field, marking the group's transition from the research and development stage to the commercialization stage. After the launch, the company will further promote the commercialization of cosmetic products globally, provide more convenient and effective product options for consumers with hair loss prevention needs, and plan to allocate more resources in the future to enhance the group's commercial capabilities, increase brand awareness, grasp market dynamics, and increase product penetration rate.